Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016

Ignacio Valero(Instituto de Salud Carlos III), Juan González‐García(Hospital Universitario La Paz), María Jesús Vivancos(Hospital Universitario Ramón y Cajal), Ignacio de los Santos, Pablo Ryan, Sara de la Fuente-Moral(Hospital Universitario Puerta de Hierro Majadahonda), María Yllescas(Fundación Seimc-Gesida), Joanna Cano(Hospital Universitario La Paz), Guillermo Cuevas(Hospital Universitario Infanta Leonor), Alicia González(Hospital Del Mar), Alberto Díaz de Santiago, Guadalupe Rúa(Fundación Seimc-Gesida), Miguel Górgolas(Hospital Universitario Fundación Jiménez Díaz), Alfonso Cabello(Hospital Universitario Fundación Jiménez Díaz)
Open Forum Infectious Diseases
October 17, 2020
10.1093/ofid/ofaa482
Cited by 8

Related Papers

Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
|Clinical Microbiology and Infection|2020|423
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
|PLoS ONE|2018|179
Severe Dengue Virus Infection in Travelers: Risk Factors and Laboratory Indicators
|The Journal of Infectious Diseases|2007|173
Hospital-Acquired Infectious Endocarditis Not Associated with Cardiac Surgery: An Emerging Problem
|Clinical Infectious Diseases|1995|170